These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21142615)

  • 1. Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA).
    Karamanos B; Thanopoulou A; Drossinos V; Charalampidou E; Sourmeli S; Archimandritis A;
    Curr Med Res Opin; 2011 Feb; 27(2):303-13. PubMed ID: 21142615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
    Lester JW; Fernandes AW
    Int J Clin Pract; 2005 Feb; 59(2):134-42. PubMed ID: 15854187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
    Peters Harmel AL; Kendall DM; Buse JB; Boyle PJ; Marchetti A; Lau H
    Curr Med Res Opin; 2004; 20(2):215-23. PubMed ID: 15006017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.
    Tseng CH; Huang TS
    Diabetes Res Clin Pract; 2005 Nov; 70(2):193-4. PubMed ID: 16188579
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical evaluation of combined therapy for type 2 diabetes.
    Rodríguez A; Ciprés L; Tofé S; Polavieja P; Reviriego J
    Curr Med Res Opin; 2010 May; 26(5):1171-83. PubMed ID: 20297952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.
    Derosa G; Tinelli C; Maffioli P
    Diabetes Obes Metab; 2009 Dec; 11(12):1091-9. PubMed ID: 19765050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
    Hansen RA; Farley JF; Droege M; Maciejewski ML
    Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
    González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
    J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
    Davidson JA; Perez A; Zhang J;
    Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
    Ceriello A; Johns D; Widel M; Eckland DJ; Gilmore KJ; Tan MH
    Diabetes Care; 2005 Feb; 28(2):266-72. PubMed ID: 15677777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sulfonylurea-pioglitazone combination agent].
    Hashiramoto M; Kaku K
    Nihon Rinsho; 2012 May; 70 Suppl 3():633-41. PubMed ID: 22768590
    [No Abstract]   [Full Text] [Related]  

  • 20. Pioglitazone: a review of its use in type 2 diabetes mellitus.
    Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM
    Drugs; 2006; 66(1):85-109. PubMed ID: 16398569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.